Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

3.50
+0.16004.79%
Post-market: 3.500.00000.00%19:59 EDT
Volume:22.90M
Turnover:80.71M
Market Cap:1.87B
PE:-3.42
High:3.63
Open:3.39
Low:3.37
Close:3.34
52wk High:7.18
52wk Low:2.77
Shares:535.00M
Float Shares:522.33M
Volume Ratio:1.28
T/O Rate:4.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0219
EPS(LYR):-1.4410
ROE:-56.58%
ROA:-27.33%
PB:2.05
PE(LYR):-2.43

Loading ...

Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years

Reuters
·
Mar 25

Recursion Pharmaceuticals CFO Ben R Taylor disposes of USD 51,000 in common shares

Reuters
·
Mar 19

Rose the dog might have just heralded the age of programmable medicine - and here are the stocks that benefit

Dow Jones
·
Mar 17

A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress

Simply Wall St.
·
Mar 12

Recursion Pharmaceuticals CEO and President Najat Khan Disposes of Common Shares

Reuters
·
Mar 12

Insiders Cash Out: GE Vernova, Recursion, Axon, Seagate, Energy Fuels

TIPRANKS
·
Mar 07

Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum

TIPRANKS
·
Mar 07

Recursion Pharmaceuticals Director Blake Borgeson Disposes of Common Shares

Reuters
·
Mar 05

Stock Track | Recursion Pharmaceuticals Soars 5.08% Intraday Amid Nvidia Concept Stocks Rally

Stock Track
·
Mar 04

Nvidia Concept Stocks Rally. Nebius Up 9%; Applied Digital And CoreWeave Up 8%; WhiteFiber Up 7%; Core Scientific Up 6%; WeRide And Recursion Up 4%

Tiger Newspress
·
Mar 04

Recursion Pharmaceuticals Publishes 2025 Shareholder Letter

Reuters
·
Feb 28

Nvidia-Linked Shares Fall. CoreWeave Plunged over 17%; Nebius Down 8%; APLD Down 5%; Nvidia Down 2.5%

Tiger Newspress
·
Feb 27

Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham

Dow Jones
·
Feb 26

Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA

TIPRANKS
·
Feb 26

Balanced Risk-Reward Keeps Recursion at Hold as Key Clinical Catalysts Remain Longer-Dated

TIPRANKS
·
Feb 26

Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)

TIPRANKS
·
Feb 26

What's Behind The Jump In Recursion Pharmaceuticals Stock?

Benzinga
·
Feb 25

Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
Feb 25

Recursion Pharmaceuticals Inc - May Sell Class a Stock up to $300 Mln - SEC Filing

THOMSON REUTERS
·
Feb 25

Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments

Reuters
·
Feb 25